ODN2216 is used as a human-specific TLR9 (Toll-like receptor 9) agonist to induce high levels of IFN-α and IFN-β; it stimulates plasmacytoid dendritic cells (pDCs) to produce IFN-α and dendritic cells (DCs) to secrete IL-12 (p40); it activates peripheral blood mononuclear cells (PBMCs) to produce IFN-γ indirectly via IFN-α/β mediation; it enhances NK cell activation and promotes IFN-γ production in TCR-stimulated CD4+ T cells.